Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pragmatic Randomized Phase III Trial to Assess the Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

NCT06476184 is registered in ClinicalTrials.gov with ARCAGY/ GINECO GROUP as lead sponsor.

NCT NCT06476184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06476184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pragmatic Randomized Phase III Trial to Assess the Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Lead sponsor
ARCAGY/ GINECO GROUP
Phase
Phase 3
Overall status
Recruiting
Start date
July 30, 2024
Completion date
June 30, 2028
Enrollment
250 (estimated)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer